- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00417742
Project CHEER (Comprehensive Headache Evaluation, Education, Relief)
A Randomized Trial of Headache Management Programs
PROJECT CHEER is a randomized controlled trial designed to test the effectiveness of a comprehensive focused approach to headache care. Three institutions are collaborating in this trial by establishing special Headache Programs that can provide individualized treatment and follow-up: Duke University Medical Center in Durham, NC; Thomas Jefferson University in Philadelphia, PA; and Kaiser Permanente in San Diego, CA. Support and oversight are provided by the U.S. Agency for Healthcare Research and Quality.
HEADACHE sufferers age 18 and over whose headaches interfere with their ability to work, study or enjoy life are eligible for this trial. Half of the enrolled individuals will be selected at random to receive care in the Headache Program and half will continue to receive care as usual from their primary care providers.
EVALUATION is an important part of this project. Every participant completes a screening interview and survey at the time of enrollment. The initial evaluation will provide an accurate diagnosis of headache type(s). The results of this evaluation will be reported to the primary care provider and may help to provide usual care. Subjects assigned to the Headache Program are further evaluated by the program manager in consultation with a headache specialist.
EDUCATION in headache care is provided to participants assigned to the Headache Program.
The classes include suggestions on diet and lifestyle as well as a review of medication use.
Note: The above is excerpted from the flyer we distributed to recruit patients to the trial.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this study is to determine whether headache management programs should be promoted as a preferred strategy for managing patients with chronic disabling headache.
Chronic headache affects between 6% and 17% of the population and is associated with significant numbers of days lost from work and reduced quality of life, as well as disproportionate use of medical resources. Current treatment is sub-optimal, with patients often not adequately diagnosed and/or not receiving appropriate preventive and acute pharmacologic therapy or behavioral modification. As a result, chronic headache is associated with sub-optimal quality of care, high patient dissatisfaction as well as high cost to individuals, insurers, and society.
The specific hypothesis of this study is that a properly designed headache management program (HMP) will reduce headache-related disability, improve process of care, and reduce management costs for patients with chronic headache. The format is a randomized controlled trial in which a patient population participating in a HMP will be compared with a corresponding patient population receiving usual care. A pilot study1 has determined the components of an optimal HMP and the effectiveness of a prototype of this service with a limited number of patients at a Kaiser Permanente facility in Santa Rosa, California.
Type d'étude
Inscription
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Diego, California, États-Unis, 92120
- Kaiser Permanente
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Thomas Jefferson University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- age 21 or over
- have chronic headache thought to be of tension-type, migraine or mixed etiology
- intend to continue headache care at their current location for the next six months
- MIDAS score >5
Exclusion Criteria:
- Under age 21
- Currently seeing a neurologist for headache care
- Currently being seen in a Headache Clinic
- MIDAS score <5
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
---|
MIDAS, simple and accurate five-question survey that measures days lost to headache disability during the last 3 months and also headache pain on a 10-point scale.
|
The measure is taken by telephone at the screening interview and by mailed survey at basel
|
Mesures de résultats secondaires
Mesure des résultats |
---|
CATI headache diagnostic survey is administered by telephone at the screening interview to obtain a diagnosis of headache type.
|
SF-36 Quality of Life Survey is administered by mailed survey at baseline and at 6 and 12 months
|
Health Care Utilization Measures will include self-report by patients on the mailed surveys at baseline and at 3, 6 and 12 months.
|
Patients are asked about their use of outpatient, inpatient and emergency room services, as well as use of alternative therapies (e.g., accupuncture, massage therpay, herbalists) and prescription and nonprescription drugs.
|
Patient reports will be validated by administrative utilization data and by a limited chart review at each site.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: David B Matchar, MD, Duke University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 0728
- AHRQ Grant No.: 1 R01 HS10893
- 0728-06-5R7ER
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Maux de tête chroniques
-
PfizerComplétéLeucémie, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) PositifFrance, États-Unis, Canada, Espagne, Tchéquie, Singapour, Thaïlande, Danemark, Norvège, Corée, République de, Finlande, Hongrie, Suède, Pays-Bas, Italie, Allemagne, Ukraine, Afrique du Sud, Taïwan, Australie, Belgique, Israël, Mexique, Pologn... et plus